The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Dec 2014
Randomized Controlled Trial Multicenter StudyDupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
Severe atopic dermatitis (AD) has a high unmet need for effective and safe therapeutics. In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor α, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized. ⋯ This is the first report showing rapid improvement of the AD molecular signature with targeted anti-IL-4 receptor α therapy. These data suggest that IL-4 and IL-13 drive a complex, TH2-centered inflammatory axis in patients with AD.